Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma drug R&D as it also develops the technology for clinical care applications.
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy -- and those who won't. The latest trial results extend the test's reach.
Molecular diagnostics companies have laid the foundation for nothing short of a revolution in cancer care — it’s time for the medtech sector to develop tools to make genomic testing accessible to the masses.
On the back of that symbolic FDA approval, Foundation Medicine's Gaurav Singal discussed the latest innovations for expanding access to precision medicine beyond the major academic centers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Running low on talking points for your liquid biopsy watercooler chats? Fear not. An education session at ASCO 2017 highlighted some of the latest findings from the field — and we have a recap of that recap here.
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is 'yes.'
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed "Guardant 1 million," the push will be financed with $360 million in new financing from a broad syndicate of investors.
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail's pan-cancer screening test.
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.